Market Signal Briefing

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Accuray Incorporated (NASDAQ:ARAY) Shareholder/Analyst Call September 29, 2025 4:30 PM EDT

Company Participants

Suzanne Winter - President, CEO & Director
Mu Lee - Senior Vice President of Research & Product Development
Seth Blacksburg - Senior VP & Chief Medical Officer

Conference Call Participants

Shalom Kalnicki
Jonathan Haas
Giuseppe Sasso
John Kresl

Presentation

Suzanne Winter
President, CEO & Director

Good afternoon, everyone, and welcome to Accuray's Analyst briefing. We're coming to you from the ASTRO conference in San Francisco for 2025. We'll be leading a discussion about leading in the adaptive era of radiation medicine. I want to welcome everyone. It's absolutely a privilege to be here with a distinguished group of our global key opinion leaders in radiation oncology as well as our research analysts and shareholders who are joining us virtually. Our analysts that cover medtech and radiation oncology market, and they write notes for investors and advise on investment decisions. You're all experts and who -- how we shape, how we understand innovation in medical technology and how we bridge clinical insight, patient outcomes and investment perspectives.

As you know, at Accuray, we believe our role is not just to build devices, but to advance medicine by partnering with clinicians and researchers who set the standard of care. Today, we're going to have an open dialogue about the trends in adaptive radiation medicine treatment. We'll be sharing science behind the technology and hearing perspectives from our esteemed panel, and we'll be exploring how we can make the greatest impact for patients and health care systems to deliver clinical and economic value. So thank you for taking the time to be here. We'll dive into the conversation. I'll make a few opening remarks, and then we'll go right into the discussion.

Let's start with our safe harbor statement. And again, this is a presentation that

Recommended For You

DULUTH, Ga.--(BUSINESS WIRE)--The latest Primerica Household Budget Index™ (HBI™) data, a monthly economic metric that examines how inflation and wage trends impact the ability of middle-income families to afford life's everyday necessities, was 100.2% in August, a 0.1% increase from a month ago and up 0.8% from a year ago. The Consumer Price Index (CPI), which measures inflation for a comprehensive basket of goods for all U.S. households, rose 2.9% in August compared to a year ago marking the.

Exxon Mobil logo and stock graph are seen through a magnifier displayed in this illustration taken September 4, 2022. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

CompaniesSept 30 (Reuters) - ExxonMobil's

(XOM.N), opens new tab chief executive Darren Woods sought assurances from Mozambique's president Daniel Chapo last week about security for a proposed $30 billion gas terminal in the country ahead of a decision to greenlight the project, the Financial Times reported on Tuesday.

Woods raised concerns about the dangers posed by a jihadist insurgency in Mozambique’s north-eastern Cabo Delgado region, where Exxon is planning to build Africa's largest LNG facility, the report said, citing sources with knowledge of the talks.

Sign up here.

Reuters could not immediately verify the report. Exxon did not immediately respond to a Reuters' request for comment. The Mozambican presidency could not be reached immediately.

Islamic State-linked militants launched an insurgency in the northern gas-rich province of Cabo Delgado in 2017, killing thousands of civilians, destroying livelihoods and internally displacing hundreds of thousands, aid agencies say. The insurgency has disrupted multi-billion-dollar energy projects.

Woods and Chapo also discussed plans by TotalEnergies

(TTEF.PA), opens new tab to resume work on a nearby LNG facility being developed by the French oil major and lift a force majeure, the FT said.

TotalEnergies had halted work on the project and declared force majeure in 2021 after insurgents attacked the northern town of Palma, a logistics hub near the site.

"We strongly believe that the ExxonMobil project, if implemented, will make a huge difference in the economy of Mozambique and, as a consequence, in the life of Mozambicans," Chapo told the FT in an emailed statement.

An Exxon spokesperson told the FT that the company is working closely with Total, the Mozambique government and its partners in the LNG project to ensure the right conditions are met to enable a final investment decision on the development.

Reporting by Rhea Rose Abraham in Bengaluru; Editing by Mrigank Dhaniwala

Our Standards: The Thomson Reuters Trust Principles., opens new tab

"The competitive reality is that the Chinese are the 700-pound gorilla in the EV industry," Ford CEO Jim Farley said of Chinese automakers.

Kym Illman via Getty Images

2025-09-30T04:24:42Z

Ford CEO Jim Farley says China is dominating the global EV market.
"The competitive reality is that the Chinese are the 700-pound gorilla in the EV industry," he said.
Farley said China's success stems from the government's support, which their automakers get to enjoy.

Ford CEO Jim Farley says there's barely any contest between Chinese and American automakers when it comes to dominating in EVs.

"The competitive reality is that the Chinese are the 700-pound gorilla in the EV industry," Farley told The Verge's "Decoder" podcast in an episode that aired Monday.

"There's no real competition from Tesla, GM, or Ford with what we've seen from China. It is completely dominating the EV landscape globally and more and more outside of China," he added.

Representatives for Farley at Ford did not respond to a request for comment from Business Insider.

Farley told guest host and journalist Joanna Stern that China's dominance in the industry stemmed from the generous government support its automakers enjoyed.

"China's successful for good reason. It has great innovation at a very low cost," Farley said.

"There's hundreds of companies, and they're all sponsored by their local governments, so they have huge subsidies. It's new brands. It's BYD and Geely, and companies like Nio and Xiaomi, many of which have never been in the car business before, and that's a big advantage for them," he added.

Farley has talked about China's lead in the EV race on multiple occasions.

In June, Farley said during a panel at the Aspen Ideas Festival that China's EV progress is the "most humbling thing" he has ever seen.

"They have far superior in-vehicle technology. Huawei and Xiaomi are in every car," Farley said. "You get in, you don't have to pair your phone. Automatically, your whole digital life is mirrored in the car."

"We are in a global competition with China, and it's not just EVs. And if we lose this, we do not have a future Ford," he added.

Farley praised Chinese tech giant Xiaomi's maiden electric vehicle, the SU7, in an episode of "The Fully Charged Podcast," which aired in October 2024.

"I don't like talking about the competition so much, but I drive the Xiaomi," Farley said.

"We flew one from Shanghai to Chicago, and I've been driving it for six months now, and I don't want to give it up," he added.

Farley isn't the only one who sees China's dominance in EVs as a byproduct of the country's lower labor costs and generous subsidies.

The Centre for Strategic & International Studies said in a report published last year that China's government has spent at least $230 billion funding local EV makers between 2009 and 2023.

"There's not something magical when you take it apart that's allowing these really impressive cost structures," RJ Scaringe, the CEO of American EV maker Rivian, told the "Everything Electric" podcast in an episode that aired in September.

"There's no secret magic thing that you're like, 'Oh, aha, they did this.' But rather it's the compounding benefits of a lower cost of capital," he added.

Ford

China

Read next

TOKYO--(BUSINESS WIRE)--Accenture (NYSE: ACN) is set to acquire Aidemy Inc. (President: Akihiko Ishikawa, Tokyo Stock Exchange Growth Market, Securities Code: 5577), after completing a tender offer. Integrating Aidemy into Accenture will further strengthen LearnVantage, Accenture’s learning and reskilling service, which is helping clients around the world to identify and fill skill gaps in their businesses, and train their people in areas like generative AI which are essential for promoting enterprise reinvention utilizing advanced technologies. Additionally, this acquisition will strengthen Accenture’s ability to provide end-to-end support for clients to reinvent with AI—from talent development to ensuring the sustained use of AI systems—by leveraging Aidemy’s expertise in developing, implementing, and operating AI systems optimized for a wide range of tasks and industries.

During the tender offer period from August 15, 2025 (Friday) through September 29, 2025 (Monday), the number of Aidemy’s common shares and stock acquisition rights tendered to Accenture exceeded the minimum number of shares to be purchased, and accordingly, the tender offer was successfully completed. Upon completion of the settlement of the tender offer, Aidemy will become a subsidiary of Accenture. Accenture is to purchase all remaining shares and stock acquisition rights in the coming months, after which Aidemy will be delisted from the Tokyo Stock Exchange.

Aidemy provides AI and digital transformation (DX) support services for enterprises, including talent development, organizational transformation consulting and AI system development. For individuals, Aidemy has developed high expertise in areas such as reskilling programs focused on AI, DX and data analysis, as well as career support. Founded in June 2014, Aidemy was listed on the Tokyo Stock Exchange Growth Market in June 2023. Going forward, approximately 130 professionals engaged within Aidemy and its group of companies (fact-real, MABOROSHI, to-R) responsible for system development and operations will join Accenture to support clients in advancing their talent strategies and organizational transformation.

Atsushi Egawa, CEO, Accenture, Japan, and co-CEO, Asia-Pacific, said: "There is a growing demand among companies to rapidly drive comprehensive total enterprise reinvention utilizing cutting edge technologies, including generative AI. To ensure the success of such transformations, it is essential not only to redefine ways of working and skills based on digital and AI utilization, but also to focus on talent development and redeployment. By combining the strengths of Aidemy group and Accenture, we can support enhancing competitiveness and sustainable growth by maximizing the potential of our clients’ workforces. Additionally, we aim to fundamentally transform the way learning is conducted and contribute to building a foundation that supports the growth of society as a whole."

Akihiko Ishikawa, President, Aidemy said: "Aidemy group has over its history provided end-to-end support across the AI and DX domains in fields ranging from education to development and implementation, thereby helping to drive corporate transformation. We are confident that joining Accenture will enable us to further expand our expertise in talent development and our technical capabilities for AI system development. In particular, we will strengthen reskilling which can be utilized in on-the-job activities and provide support for organizational adoption, which in turn will accelerate companies’ processes for incorporating AI, generative AI, and other advanced technologies into their businesses. Under our mission, 'Bringing advanced technology into the economy,' we will accelerate efforts to strengthen the competitiveness and talent development of leading companies in Japan and around the world, and contribute to the digitalization of society."

According to a survey by the World Economic Forum, on average, workers can expect that two-fifths (39%) of their existing skill sets will be transformed or become outdated over the 2025-2030 period1. This makes continuous investment in talent development essential for companies to maintain their competitiveness. In this context, Accenture announced in March 2024 a US$1 billion investment over three years to establish LearnVantage, a comprehensive service which supports talent strategies, reskilling and upskilling for clients around the globe. To strengthen this offering, Accenture has made a series of acquisitions including Udacity, Award Solutions, TalentSprint and Ascendient Learning.

About Accenture

Accenture is a leading global professional services company that helps the world’s leading businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services—creating tangible value at speed and scale. We are a talent- and innovation-led company with approximately 779,000 people serving clients in more than 120 countries. Technology is at the core of change today, and we are one of the world’s leaders in helping drive that change, with strong ecosystem relationships. We combine our strength in technology and leadership in cloud, data and AI with unmatched industry experience, functional expertise and global delivery capability. Our broad range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song, together with our culture of shared success and commitment to creating 360° value, enable us to help our clients reinvent and build trusted, lasting relationships. We measure our success by the 360° value we create for our clients, each other, our shareholders, partners and communities. Visit us at accenture.com

Forward-Looking Statements

Except for the historical information and discussions contained herein, statements in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “should,” “likely,” “anticipates,” “aspires,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” “positioned,” “outlook,” “goal,” “target” and similar expressions are used to identify these forward-looking statements. These statements are not guarantees of future performance nor promises that goals or targets will be met, and involve a number of risks, uncertainties and other factors that are difficult to predict and could cause actual results to differ materially from those expressed or implied. These risks include, without limitation, risks that: Accenture and Aidemy will not be able to close the transaction in the time period anticipated, or at all, which is dependent on the parties’ ability to satisfy certain closing conditions; the transaction might not achieve the anticipated benefits for Accenture; Accenture’s results of operations have been, and may in the future be, adversely affected by volatile, negative or uncertain economic and geopolitical conditions and the effects of these conditions on the company’s clients’ businesses and levels of business activity; Accenture’s business depends on generating and maintaining client demand for the company’s services and solutions including through the adaptation and expansion of its services and solutions in response to ongoing changes in technology and offerings, and a significant reduction in such demand or an inability to respond to the evolving technological environment could materially affect the company’s results of operations; risks and uncertainties related to the development and use of AI could harm the company’s business, damage its reputation or give rise to legal or regulatory action; if Accenture is unable to match people and their skills with client demand around the world and attract and retain professionals with strong leadership skills, the company’s business, the utilization rate of the company’s professionals and the company’s results of operations may be materially adversely affected; Accenture faces legal, reputational and financial risks from any failure to protect client and/or company data from security incidents or cyberattacks; the markets in which Accenture operates are highly competitive, and Accenture might not be able to compete effectively; Accenture’s ability to attract and retain business and employees may depend on its reputation in the marketplace; if Accenture does not successfully manage and develop its relationships with key ecosystem partners or fails to anticipate and establish new alliances in new technologies, the company’s results of operations could be adversely affected; Accenture’s profitability could materially suffer due to pricing pressure, if the company is unable to remain competitive, if its cost-management strategies are unsuccessful or if it experiences delivery inefficiencies or fail to satisfy certain agreed-upon targets or specific service levels; changes in Accenture’s level of taxes, as well as audits, investigations and tax proceedings, or changes in tax laws or in their interpretation or enforcement, could have a material adverse effect on the company’s effective tax rate, results of operations, cash flows and financial condition; Accenture’s results of operations could be materially adversely affected by fluctuations in foreign currency exchange rates; Accenture’s debt obligations could adversely affect its business and financial condition; changes to accounting standards or in the estimates and assumptions Accenture makes in connection with the preparation of its consolidated financial statements could adversely affect its financial results; as a result of Accenture’s geographically diverse operations and strategy to continue to grow in key markets around the world, the company is more susceptible to certain risks; if Accenture is unable to manage the organizational challenges associated with its size, the company might be unable to achieve its business objectives; Accenture might not be successful at acquiring, investing in or integrating businesses, entering into joint ventures or divesting businesses; Accenture’s business could be materially adversely affected if the company incurs legal liability; Accenture’s work with government clients exposes the company to additional risks inherent in the government contracting environment; Accenture’s global operations expose the company to numerous and sometimes conflicting legal and regulatory requirements; if Accenture is unable to protect or enforce its intellectual property rights or if Accenture’s services or solutions infringe upon the intellectual property rights of others or the company loses its ability to utilize the intellectual property of others, its business could be adversely affected; Accenture may be subject to criticism and negative publicity related to its incorporation in Ireland; as well as the risks, uncertainties and other factors discussed under the “Risk Factors” heading in Accenture plc’s most recent Annual Report on Form 10-K, as updated in Item 1A, “Risk Factors” in its Quarterly Report on Form 10-Q for the second quarter of fiscal 2025, and other documents filed with or furnished to the Securities and Exchange Commission. In addition, the timing and amount of costs related to our business optimization actions and the nature and extent of benefits realized from such actions are subject to uncertainties and other factors, including local country consultation processes and regulations, and may differ from our current expectations and estimates. Statements in this news release speak only as of the date they were made, and Accenture undertakes no duty to update any forward-looking statements made in this news release or to conform such statements to actual results or changes in Accenture’s expectations.

1Source: Future of Jobs Report 2025, World Economic Forum, January 7, 2025.

Copyright © 2025 Accenture. All rights reserved. Accenture and its logo are trademarks of Accenture.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies Entered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Invested in Stalicla SA, confirming commitment to advancing innovative treatments for CNS disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2025, and provided a corporate update.

Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies.The test helps clinicians quickly identify heart attack and rule out non-cardiac causes, ensuring patients receive the care they need at the earliest opportunity.The global TSIX clinical study involved more than 13,000 participants, validating performance across a diverse population that reflects real-world healthcare settings.1,2 Basel, 30 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the primary results from the TSIX Study Program, which evaluated the performance of its new sixth-generation high-sensitivity Troponin T test for diagnosing heart attacks. Presented at the European Society for Emergency Medicine (EUSEM) 20252 and the European Society of Cardiology (ESC) 20251, the study results showed that the Elecsys® Troponin T hs Gen 6 test was able to identify acute myocardial infarction (AMI), or heart attack, and identify those not having an AMI, with a high level of precision.2,3 This supports the efficient triage of patients arriving at the emergency department, ensuring healthcare resources can be focused where they are needed most. This data announcement follows the recent CE Mark approval for the test.

As one of the top three reasons for emergency care visits,4 chest pain creates significant anxiety and uncertainty for patients whilst putting pressure on healthcare services. Yet only one in every ten patients who presents with symptoms will actually be experiencing a heart attack.5 With 49% of emergency departments in Europe reporting overcrowding on a frequent basis,6 the ability to quickly and reliably identify those patients who are suffering from AMI, and to rule out those who are not, is crucial in ensuring the best possible outcomes for patients.

"Coronary artery disease continues to place an immense strain on global health systems, particularly in emergency care, where cases of chest pain are among the most challenging presentations to evaluate,” said Matt Sause, CEO of Roche Diagnostics. “Our new test enables clinicians to detect even the smallest elevations in troponin levels – a critical biomarker for heart attack – with high confidence. This ensures that in a situation when every second counts, patients receive the life-saving care they need at the earliest opportunity, and emergency services can prioritise resources to deliver care effectively to those in urgent need."

About Roche Diagnostics’ commitment to heart health
With a 30-year legacy in troponin innovation, Roche was the first company in the world to introduce high-sensitivity troponin tests. And Roche's troponin test was the first to receive FDA approval. Building on this legacy, the novel test is the first in a series of anticipated approvals for Roche, reflecting the company's vision for the future of coronary artery disease (CAD) management. This includes a portfolio of innovative tests that enable consistent and precise biomarker measurements to be reliably compared across healthcare settings. It also includes future acute coronary syndrome (ACS) offerings that will combine next-generation digital algorithms, biomarkers, near-patient care devices, and laboratory analysers.

About the TSIX Study Program
Forming the basis for regulatory approval, the comprehensive TSIX study program recruited a total of over 13,000 individuals.1,4 It is the first global clinical study program of its kind to be performed in the use of troponin testing, involving patients in the US, China, Japan and the EU, and reflects Roche’s ambition to work towards more standardised care across the world.

The REF-TSIX study was designed to establish the standard upper reference limits (URLs) for troponin levels in the blood.1 These limits represent the highest expected concentration of troponin in a healthy population, providing the benchmarks used to diagnose myocardial infraction. The study prospectively collected plasma and serum samples from a diverse global population to ensure the assay's accuracy across different demographics and healthcare settings. Data presented at European Society of Cardiology congress 2025 showed a 99th percentile URLs of 27 ng/L for the overall population and sex-specific URLs of 18 ng/L for females and 32 ng/L for males.1 These findings confirm the test's consistency and accuracy, meeting the highest benchmarks for clinical diagnostics as recommended by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).7

To validate the clinical performance of the newly established URLs, the prospective, international, multicenter, longitudinal cohort study PERFORM-TSIX enrolled 5,631 patients across 50 sites,2,4 presenting to emergency departments with symptoms of ACS. Up to five samples were collected at intervals after presentation at the emergency department, to provide a detailed assessment of the test's performance across time points.4

The study data demonstrated that the assay was highly effective at detecting heart attacks, meeting its primary endpoint using the universal 99th percentile URL at three hours post emergency department presentation.3 Moreover, the study data showed that 56.6% of patients were able to be discharged in the first hours after presentation with a negative predictive value of 99.7%, underlining its excellent clinical performance.2,4

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Daniels LB et al. Establishing reference values in healthy participants for a next generation cardiac troponin T high-sensitivity assay – the REF-TSIX global reference study. Presented at European Society of Cardiology Congress. 2025 August
[2] Peacock WF et al. Primary results of PERFORM-TSIX, a prospective, international, observational, longitudinal cohort study evaluating clinical performance of the next generation cardiac troponin T high-sensitivity Gen 6 assay in acute coronary syndrome myocardial infarction. Presented at European Society of Emergency Medicine September 2025
[3] F. Hoffmann-La Roche Ltd. Elecsys® Troponin T hs Gen 6 Method Sheet. (v.2.0). 2025
[4] Audrey J. Weiss, Ph.D., and H. Joanna Jiang, Ph.D., Agency for Healthcare Research and Quality, Most Frequent Reasons for Emergency Department Visits, 2018. Available at: https://hcup-us.ahrq.gov/reports/statbriefs/sb286-ED-Frequent-Conditions-2018.jsp
[5] Fanaroff AC, Rymer JA, Goldstein SA, Simel DL, Newby LK. Does This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review. JAMA. 2015 Nov 10;314(18):1955-65. doi: 10.1001/jama.2015.12735. PMID: 26547467.
[6] Velt KB, Cnossen M, Rood PPM, Steyerberg EW, Polinder S, Lingsma HF; CENTER-TBI investigators. Emergency department overcrowding: a survey among European neurotrauma centres. Emerg Med J. 2018 Jul;35(7):447-448. doi: 10.1136/emermed-2017-206796. Epub 2018 Mar 21. PMID: 29563151.
[7] Aakre, K. M., Saenger, A. K., Body, R., Collinson, P., Hammarsten, O., Jaffe, A. S., ... & Apple, F. S. (2022). Analytical considerations in deriving 99th percentile upper reference limits for high-sensitivity cardiac troponin assays: educational recommendations from the IFCC committee on clinical application of cardiac bio-markers. Clinical chemistry, 68(8), 1022-1030.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected]

Hans Trees, PhD
Phone: +41 79 407 72 58 Sileia Urech
Phone: +41 79 935 81 48 Nathalie Altermatt
Phone: +41 79 771 05 25 Lorena Corfas
Phone: +41 79 568 24 95 Simon Goldsborough
Phone: +44 797 32 72 915 Karsten Kleine
Phone: +41 79 461 86 83 Kirti Pandey
Phone: +49 172 6367262 Yvette Petillon
Phone: +41 79 961 92 50 Dr Rebekka Schnell
Phone: +41 79 205 27 03   Roche Investor Relations

Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: [email protected] Dr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: [email protected] Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: [email protected]   Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: [email protected]  

Media Investor Release Troponin T Test English

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The Bitcoin community is no stranger to heated debates, but the latest controversy around a rumored Bitcoin Redaction Fork has reignited one of the oldest philosophical battles in crypto: should Bitcoin remain an untouchable, immutable ledger, or should it adapt to external pressures to remove illicit or arbitrary data

Institutional confidence in Solana (SOL) remains strong, making it one of the stable altcoins in the market. Treasury wallets now hold over 20.9 million SOL, roughly 3.64% of the total supply, indicating that large investors are increasingly viewing SOL alongside Bitcoin and Ethereum as part of diversified crypto portfolios.

Companies like Forward Industries and Brera Holdings have disclosed their asset exposure, while ARK has added Solana-related equities and continues to emphasize the network’s expansion.

Meanwhile, speculation about a potential Solana staking ETF has gained momentum; if approved, it could reduce circulating supply and provide yield access, potentially attracting significant new capital into SOL. Mid-cycle analyst targets of $300–$500 reflect this institutional interest along with rising on-chain activity.

SOL's price trends to the upside but with some losses on the daily chart. Source: SOLUSD chart on Tradingview
Firedancer + Alpenglow: Leap in Performance vs. Decentralization Risk
Solana’s technology roadmap provides another boost. Jump Crypto’s Firedancer client proposes SIMD-0370 to remove the fixed compute block limit, allowing higher-performance validators to process more complex blocks and increasing overall throughput.

At the same time, the Alpenglow upgrade (testnet scheduled for December) aims to drastically reduce transaction finality, from approximately 12.8 seconds to 150 milliseconds, making Solana the fastest major chain. These changes could strengthen Solana’s leadership in high-volume DeFi and payments.

However, critics warn that increasing centralization may occur if smaller validators cannot afford the necessary hardware upgrades. The primary challenge is striking a balance between raw speed and validator diversity, which is crucial for evaluating the network’s long-term resilience.

Price Levels: Can Solana (SOL) Bulls Defend $207?
Currently, SOL hovers near $208–$210, up modestly on the day as momentum rebuilds. The market now focuses on $207 as the first support level; a sustained hold preserves the uptrend and keeps a retest of $230–$253 possible, with $257 (the 52-week high) remaining above.

Losing $207 opens the door to $190–$185 as the next demand zone, and a deeper shakeout could test $165–$167. Short-term sentiment is supported by improving tape dynamics, higher spot volumes, and active addresses, although macro factors remain a swing factor.

For traders, the constructive setup is to hold $207, reclaim $223–$230, and then challenge $253–$257. For investors, the thesis relies on three pillars: increasing treasury ownership and potential ETF catalysts, throughput leadership from Firedancer and Alpenglow, and expanding real-world utility across DeFi and commerce.

If Solana maintains support while upgrades happen as scheduled, the path toward new highs strengthens; if not, expect a choppy Q4 with value emerging around the $185 area.

Cover image from ChatGPT, SOLUSD chart from Tradingview

Solana whale sells $31.59M in $SOL, yet charts hint at bullish continuation with eyes on $250 resistance.

Izabela Anna2 min read

30 September 2025, 01:10 AM

Image: ShutterstockSolana ($SOL) has experienced a dynamic trading session as whales aggressively adjust their positions. Today, a single whale reportedly sold $31.59 million in $SOL, highlighting significant profit-taking on minor price pumps, according to analyst TedPillows. Despite this selling pressure, the market shows potential for continued upside if key technical levels hold.

Weekly Chart Hints at Bullish ContinuationAccording to CryptoJelleNL, Solana’s weekly chart shows a prominent cup-and-handle pattern forming above $180 support. The recent bounce near $206 confirms a successful retest of the breakout zone. The $250 mark remains the last hurdle for buyers, and clearing this resistance could trigger a sustained rally toward $300–$340 by year-end. 

Source: X

Conversely, a failure to overcome $250 may result in a brief pullback toward $190–$200 before another attempt. Consequently, the current setup signals bullish continuation if buyers can defend the retest and push decisively through this key resistance.

Daily Chart Insights and Liquidity SweepsOn the daily timeframe, Solana has reclaimed the 50-day simple moving average (SMA) after a brief dip, signaling renewed bullish interest, according to Umair Crypto. The recent sweep below the SMA likely gathered liquidity, setting up a potential move toward resistance around $229–$232. 

Source: X

Nevertheless, traders remain cautious, as weekend closes often spark debates about the validity of short-term movements. A confirmed close above $210 would strengthen the bullish outlook, while slipping back under the SMA could target support levels at $185 and $161.

The RSI has recovered from oversold conditions but remains mid-range, suggesting measured buying interest. With the current price around $214, $SOL has gained 3.56% in the past 24 hours, despite a 1.24% decline over the last week. Trading volumes remain robust, with $7.31 billion exchanged in the last 24 hours, reflecting active investor engagement.

Regulatory Updates Add Another LayerBeyond technical factors, regulatory news continues to influence sentiment. Journalist Eleanor Terrett reports that the SEC has asked issuers of $SOL, $LTC, $XRP, $ADA, and $DOGE ETFs to withdraw their 19b-4 filings following the approval of generic listing standards. Withdrawals could begin this week, removing some previous regulatory hurdles for crypto ETFs.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Izabela Anna

Izabela Anna is a knowledgeable freelance journalist, who boasts over five years of experience covering the cryptocurrency market. Her tenure has seen her navigate through the ebbs and flows of multiple market cycles, giving her a deep understanding within. Her journalistic focus lies in dissecting price action dynamics, scrutinizing the on-chain landscape, and providing insights from a technical perspective, making her a trusted voice in the realm of cryptocurrency reporting.

Read more about

Latest Solana (SOL) News Today

The cryptocurrency market staged a weekend rebound, with Solana (SOL), Dogecoin (DOGE), Cardano (ADA), Ethereum (ETH), and XRP among the top performers. Prices rose between 3% and 4% over the past 24 hours as short liquidations intensified, offering traders fresh optimism after a difficult week.

Bitcoin traded listlessly as September wraps up, caught inside a tight price band and showing signs of weakening momentum.

Based on reports using CryptoQuant data and commentary by Axel Adler, demand cooled after the market failed to hold above $115,000, leaving traders watching a narrow corridor for the next move. The mood is neither euphoric nor panicked — it is cautious.

Mounting Pressure At Descending Highs
Over the past week Bitcoin swung between a local high near $115,550 and a low around $108,400. For the last sessions it settled into an even tighter $108,750–109,740 band. Sellers stepped in at lower highs, keeping the price from climbing back to the prior range.

According to Adler, those descending highs are a warning sign because they show buyers are losing early ground. Immediate resistance sits around $111,000–112,000, based on on-chain flows and exchange behavior.

Move past that and bulls could try to retake $114,000–115,400. Fail to defend $108,750 and the path down may quicken toward $106,000–105,000.

Momentum Has Turned Cautious
CryptoQuant’s 30-day momentum index finished the week near -2%, down from +1% at the start, a swing of three percentage points. Momentum readings this period ranged from -6% to +1%, and only two of seven sessions closed above zero.

Those figures underline how the loss of the $114,000–115,000 support coincided with falling buying pressure. Traders often look for sustained positive momentum to confirm a rally. According to Adler, a clear recovery would need a return above $112K and several days of positive momentum to shift the tone back toward an uptrend.

BTCUSD trading at $112,173 on the 24-hour chart: TradingView
Market Structure And What It Means
The current pattern is a classic consolidation after a failed breakout. Buyers tried and failed to keep prices north of $115,000, and that shortfall left the market in a neutral-to-bearish stance.

Reports have disclosed that the week’s range and the momentum slide make an immediate strong advance unlikely without fresh demand. At the same time, there is no sign of a full-scale sell-off. Liquidity remains present near established supports.

Key Levels To Watch
A decisive push above the $111,000–112,000 resistance band could prompt a test of $114,000–115,400. The $108,600 base remains a key level. A break below it without a swift rebound could open the way toward stronger support between $106,000 and $105,000.

Shifts in on-chain demand and exchange flows are expected to provide clearer signals, as price action alone may appear steady while underlying activity changes.

Featured image from Gemini, chart from TradingView

A long-dormant Bitcoin wallet containing approximately 400 BTC—worth $44 million at today's prices—moved funds for the first time in 12 years on Sunday, according to data from blockchain analytics platforms Lookonchain and Arkham Intelligence.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Bitcoin and Ethereum ETFs experienced their worst weekly stretch since debut, as risk appetite declined and investors de-risked heading into quarter-end.

U.S. spot Bitcoin ETFs saw approximately $902.5 million in net outflows for the week of Sept. 22–26, ending a four-week inflow streak. Ethereum ETFs lost about $795.6 million, marking their largest weekly redemptions since launch.

The outflows were uneven: Fidelity’s FBTC led BTC outflows, while BlackRock’s IBIT and Invesco’s BTCO defied the trend with $173.8 million and $10 million of inflows, respectively. On the ETH side, several issuers experienced large single-day withdrawals, showing how quickly flows can reverse when macro risk increases.

Macro Headwinds Keep Buyers Cautious
The reversal came as traders weighed new U.S. tariff announcements and lingering uncertainty about the Fed’s rate cuts ahead of key inflation data. Those headlines revived fears of a growth and liquidity squeeze, driving a quick reset across risk assets.

Bitcoin briefly slipped below pivotal support intraday before rebounding, while Ethereum mirrored the move with a shallow bounce. Despite the week’s pain, September still shows net inflows for Bitcoin ETFs ($2.57B), a notable improvement from August’s outflows, evidence that institutional adoption remains intact.

For now, the market’s message is clear: without a more dovish macro backdrop or cleaner inflation prints, allocators may remain selective, trimming core BTC/ETH exposure when it is strong and adding only on clear confirmations.

BTC's price trends to the upside on low timeframes. Source: BTCUSD on Tradingview
Alternative Crypto ETFs Take Spotlight Over Bitcoin and Ethereum
Beneath the headline of redemptions, some desks report rotations toward thematic or alternative crypto ETFs (e.g., Solana, XRP) as allocators seek uncorrelated catalysts.

That discussion overlaps with speculation about a potential BlackRock XRP spot ETF, with market models suggesting $4–$8B of first-year inflows if such a product were filed and approved. Although no filing has been confirmed, XRP’s quick settlement times and low fees keep it on institutions’ radar.

Nevertheless, the week’s outflows serve as a reminder: macro factors outweigh micro in the short term. As October progresses, focus on whether BTC funds resume steady inflows, if ETH redemptions decrease, and how upcoming inflation data influences Fed expectations.

Until these factors align positively, volatility will remain high, and ETF flow reports will continue to be the best real-time indicators of institutional confidence.

Cover image from ChatGPT, BTCUSD chart from Tradingview

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Ethereum price started a recovery wave above $4,150. ETH is now consolidating and might aim for more gains if it clears the $4,220 resistance.

Ethereum remained stable above $4,020 and started a recovery wave.
The price is trading above $4,150 and the 100-hourly Simple Moving Average.
There is a connecting bullish trend line forming with support at $4,100 on the hourly chart of ETH/USD (data feed via Kraken).
The pair could continue to move up if it settles above $4,220 and $4,250.

Ethereum Price Eyes More Gains
Ethereum price remained supported above the $4,020 level and started a recovery wave, like Bitcoin. ETH price was able to recover above the $4,050 and $4,120 resistance levels.

There was a clear move above the 61.8% Fib retracement level of the downward wave from the $4,275 swing high to the $3,826 low. The bulls even pushed the price above $4,200. Besides, there is a connecting bullish trend line forming with support at $4,100 on the hourly chart of ETH/USD.

Ethereum price is now trading above $4,150 and the 100-hourly Simple Moving Average. It is also above the 76.4% Fib retracement level of the downward wave from the $4,275 swing high to the $3,826 low.

Source: ETHUSD on TradingView.com
On the upside, the price could face resistance near the $4,220 level. The next key resistance is near the $4,250 level. The first major resistance is near the $4,275 level. A clear move above the $4,275 resistance might send the price toward the $4,320 resistance. An upside break above the $4,320 region might call for more gains in the coming sessions. In the stated case, Ether could rise toward the $4,450 resistance zone or even $4,500 in the near term.

Pullback In ETH?
If Ethereum fails to clear the $4,250 resistance, it could start a fresh decline. Initial support on the downside is near the $4,150 level. The first major support sits near the $4,100 zone and the trend line.

A clear move below the $4,100 support might push the price toward the $4,050 support. Any more losses might send the price toward the $4,000 region in the near term. The next key support sits at $3,880.

Technical Indicators

Hourly MACD – The MACD for ETH/USD is gaining momentum in the bullish zone.

Hourly RSI – The RSI for ETH/USD is now above the 50 zone.

Major Support Level – $4,100

Major Resistance Level – $4,250

Joerg Hiller
Sep 30, 2025 04:13

Sui's presence at Korea Blockchain Week 2025 highlighted its growing influence in the digital asset space, featuring key discussions on AI, gaming, and blockchain advancements.

The Korea Blockchain Week (KBW) 2025 served as a significant platform for Sui, bringing together its leadership, partners, and community to spotlight its growing influence within the digital asset realm. According to Sui Foundation, the week-long series of events underscored Sui's institutional relevance and cultural impact in the Asia-Pacific region.

EastPoint: Setting the Stage
The event kicked off with EastPoint:Seoul, a private conference where key figures, including Kevin Boon, President of Mysten Labs, discussed the future of digital assets in Korea. Boon's insights into U.S. regulatory developments provided a global perspective to local stakeholders eager to understand the implications for Korean markets.

Impact and Innovation at KBW
During the KBW: IMPACT conference, Sui showcased its thought leadership and community engagement. Notable sessions included presentations by Adeniyi Abiodun and Kostas Chalkias, both Co-Founders of Mysten Labs. Abiodun introduced the Sui Stack as a coordination layer for applications and AI, while Chalkias explored blockchain's intersection with AI, highlighting new frontiers in digital technology.

Community Engagement and Gaming Focus
Midweek events focused on community-building and gaming, with over 800 partners and builders attending an elegant evening gathering in Seongsu. Industry leaders discussed the flexibility of Sui's architecture in game design and deployment. The day concluded with an interactive gaming event, "Ready. Sui. Play!" in Gangnam, engaging developers and players in hands-on experiences.

Sui Builder House: APAC
The week culminated with the Sui Builder House: APAC event, drawing 600 participants eager to explore regional strategies and product innovations. The program featured significant announcements, including new product milestones like Slush and BTCfi integrations, and showcased how partners in payments, gaming, and AI are leveraging the Sui Stack to transform their industries.

Future Prospects
The events of "Sui in Seoul" demonstrated the convergence of regulation, technology, and culture as Sui continues to strengthen its presence in the APAC region. With the success of KBW 2025, Sui is poised for further growth and innovation, with upcoming events like SuiFest in Singapore promising to build on this momentum.

Image source: Shutterstock

sui
blockchain
korea blockchain week
innovation

AlphaTON Capital has secured $71 million to strengthen its role in the Telegram ecosystem. The Nasdaq-listed firm confirmed the financing included a $36.2 million private placement and a $35 million loan facility with BitGo Prime.

Bitcoin price has rebounded from September lows as rising volumes, institutional inflows, and supportive technicals fuel expectations of a Q4 rally.

Summary

Bitcoin price rebounded to $114,603, up 2.5% in 24 hours, supported by rising trading volume and institutional inflows.
Analysts say late-September gains mark the start of a potential Q4 rally, with some forecasting new highs near $180K.
On-chain data shows accumulation by long-term holders, reduced exchange reserves, and improving technical signals.

After a volatile September, Bitcoin has gained momentum as it enters the last quarter of 2025, rising back above $114,000. Bitcoin was up 2.5% in the last day, trading at $114,603 at the time of writing. The most popular cryptocurrency is currently only 7.7% below its peak of $124,128 on Aug. 14.

Additionally, market activity has significantly increased. Following weeks of muted sentiment, the daily trading volume for Bitcoin (BTC) increased by 70% to $58.8 billion in the last 24 hours, indicating a resurgence of investor activity.

Bitcoin expected to rally into Q4
In a recent analysis, CryptoQuant contributor XWIN Research Japan explained that Bitcoin’s sharp rebound in late September was no coincidence. The Federal Reserve’s Sept. 17 interest rate cut weakened the U.S. dollar and lifted gold to new highs, setting the stage for Bitcoin to benefit as a digital alternative.

As per XWIN’s observation, capital often flows into gold first before rotating into Bitcoin as risk appetite improves, and the same pattern played out last month.

Institutional demand added fuel. The Securities and Exchange Commission’s relaxation of Exchange Traded Fund listing rules boosted confidence, leading to new XRP (XRP) and DOGE (DOGE) products and steady inflows into major funds like BlackRock’s IBIT and Fidelity’s FBTC.

XWIN concluded that these shifts, combined with reduced selling from both short- and long-term holders, show that the September rally was not a random bounce but the beginning of a stronger phase heading into Q4.

Bitcoin accumulation points to higher targets
Another CryptoQuant contributor, Carmelo Alemán, highlighted broader on-chain signals that reinforce the bullish case. Over the course of the last year, Bitcoin’s market capitalization has increased from $870 billion to $1.07 trillion, driven by average daily inflows of $385 million. Global liquidity is still growing, and large wallets and miners are gradually building up.

According to Alemán, these factors suggest that Bitcoin is currently in an accumulation phase prior to a subsequent leg up, with Q4 probably bringing new all-time highs. He went further, predicting that if institutional inflows and liquidity trends hold, Bitcoin could hit $180,000 before the year is out.

Bitcoin price technical analysis
These views are also supported by the charts. The most recent recovery was triggered by oversold relative strength index levels in September, and Bitcoin has maintained strong support between $108,000 and $110,000.

Bitcoin daily chart. Credit: crypto.news
Moving averages across all major timeframes are now flashing buy signals, suggesting the broader trend is tilted upward. Resistance remains at the $118,000 level, followed by the August all-time high around $124,000.

If these barriers are cleared, analysts argue that a rally toward $150,000 to $180,000 by year-end is plausible, provided liquidity inflows and institutional interest continue.

The Bitcoin price opened Monday with a slight recovery, reclaiming the $113,000 mark after a dip that brought the price down to $109,000—a level that has proven to be significant support for the top cryptocurrency. Despite this temporary bounce, one expert warns of further challenges ahead for bullish investors.

Warns Of Further Bitcoin Price Drops 
In a recent post on social media platform X (formerly Twitter), Doctor Profit expressed confidence in his market analysis, indicating that BTC is on track to reach his projected target range between $90,000 to $94,000, meaning an additional 20% drop for the Bitcoin price. 

He posited that the cryptocurrency is poised to move toward a new short-term downside target at approximately $106,000. According to his assessment, a minor bounce in this area could attract additional liquidity before the market potentially moves lower.

BTC’s next price target below $100,000. Source: Doctor Profit on X
Doctor Profit also paints a bleak picture of the broader economic landscape, highlighting troubling signs such as Japan’s 10-Year Bond Yield reaching its highest level since the Global Financial Crisis. 

He notes that the repo-to-reserves ratio is approaching 99%, a metric that hints at funding stress and margin strain, leading to forced selling. While he acknowledges that a surge in liquidity from central banks could provide a bullish pivot, he remains skeptical given the current market conditions.

The analyst also referenced a range of indicators and charts he has shared since August, emphasizing that many key market charts, including the Dow Jones, are at significant resistance levels, some of which have formed over a century. 

He pointed out the record levels of alleged insider selling witnessed in recent weeks, alongside a surge in retail investor inflows, suggesting a disconnect between retail enthusiasm and the actions of larger players in the market.

October Could Signal Recovery 
In contrast to Doctor Profit’s cautious stance, market expert Timothy Peterson offers a more optimistic outlook for the Bitcoin price trajectory in the months to come. Peterson believes that October could bring a positive shift for Bitcoin, drawing on historical trends and current market dynamics. 

As recently reported by NewsBTC, Peterson has outlined two potential bullish scenarios that he believes remain for the cryptocurrency: one forecasting a rise to as high as $240,000, while another more conservative estimate suggests a surge to $160,000.

As the month of September draws to a close, Doctor Profit’s prediction that Bitcoin would trade below $100,000 could still play out. With only a 9% decline needed to breach the $100,000 threshold, the outlook remains uncertain.

The daily chart shows BTC’s price recovery above $113,000. Source: BTCUSDT on TradingView.com
Featured image from DALL-E, chart from TradingView.com 

ConocoPhillips is integrating new assets as it focuses on its best properties, setting up for stronger returns when oil prices rise again.

If there is one thing that investors need to understand about the energy sector, it is that oil and natural gas prices are inherently volatile. But there's a somewhat counterintuitive takeaway here. Sometimes the best investment opportunities arise when business in the oil space isn't going so well.

Which is why investors might want to buy ConocoPhillips (COP -2.67%) today. Indeed, the company's successful business overhaul is so obvious that it is hard not to notice (at least partly because the company is so happy to point it out).

Image source: Getty Images.

Not such a great quarter for sales and earnings
ConcoPhillips' earnings in the second quarter of 2025 weren't great when you compare it to the same quarter in 2024, with a drop from $1.98 per share last year down to just $1.56 this year. But that doesn't even do justice to the energy company's earnings decline, since pulling out a one-time gain in the second quarter of 2025 drops the total down to $1.42 per share. That's the worst quarterly earnings outcome in over a year and down sequentially from even the first quarter.

But that's kind of how things go in the energy sector, where oil and natural gas prices drive the top and bottom lines of the income statement. In fact, it isn't even remotely unusual for ConocoPhillips' earnings to be volatile from quarter to quarter. That said, the energy sector is, generally, not in the best place today relative to the highs achieved in the price rebound coming out of the coronavirus pandemic.

For example, ConocoPhillips' share price has fallen around 25% from its late 2022 highs. For comparison, Brent Crude, a key international oil benchmark, and West Texas Intermediate Crude, a key U.S. oil benchmark, have both lost about a third of their value over the same span. This could actually be a good time for more aggressive investors to consider buying ConocoPhillips.

An obvious reason to like ConocoPhillips
Assuming you can stomach the uncertainty of a commodity-based business like ConocoPhillips, there are good things happening at the company. Notably, it has been integrating the acquisition of Marathon Oil and executing above expectations. For example, it added 25% more resources than projected when the deal was inked. Despite that, it also managed to reduce the number of rigs it was operating on the added properties by 30%. All in, it was able to double the business synergies it projected, saving $1 billion in costs annually. And management managed to set up $2.5 billion in dispositions in nine months, when it had previously been looking to shed $2 billion in assets over a two-year period.

The dispositions are a special consideration. ConocoPhillips isn't looking to get big for the sake of getting big. It is attempting to optimize its portfolio of assets so it can focus on only its best properties. That, in turn, should help to improve profitability over the long term. To be fair, even the best properties won't change the variability in energy prices. But wider profit margins means the company will make more money when times are good and have more downside leeway when times are bad. ConocoPhillips isn't hiding its success, it is proudly telling investors all about what it has achieved. In other words, there are obvious improvements taking shape at the business.

This is the setup for better performance in the future
To state the obvious again, as an energy company, energy prices are going to dictate ConocoPhillips' financial results. Conservative investors looking for consistent earnings or reliable dividends (the company pays a dividend regularly, but the amount of the dividend is highly variable) probably shouldn't buy the stock.

But if you are looking for direct exposure to energy prices, ConocoPhillips could be a solid choice given management's efforts to overhaul the business. When commodity prices take off again, the upgrades made to the portfolio will help supercharge ConocoPhillips' financial results. And Wall Street will almost certainly reward the stock for that.

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of AGNC, NLY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BLBD over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.